PharmaSGP Holding SE Overview
Pro stress-test →PharmaSGP is a pharmaceutical company with a broad portfolio of leading, over-the-counter (OTC) drugs and other healthcare products, with drugs based on natural pharmaceutical active ingredients with documented efficacy and virtually no known side effects. In Germany, PharmaSGP is the market leader for systemic natural pain remedies with its brand families RubaXX® for rheumatic pain and Restaxil® for neuralgic pain.
Strategic Profile
Pro stress-test →With pharmacy-exclusive products, the company has trusted brands in many relevant chronic indications that are leaders in their respective categories. The company focuses on a niche but differentiated positioning in the OTC market by emphasizing chemical-free, natural alternatives to conventional pharmaceuticals, targeting chronic conditions, pain management, and men's health across Germany.
Competitive Landscape
Pro stress-test →PharmaSGP competes in the European OTC pharmaceutical market against larger multinational players (Bayer, Novartis OTC divisions, Reckitt Benckiser) and smaller regional natural remedy producers. Its competitive advantage rests on brand recognition in natural pain relief and pharmacy-exclusive positioning in Germany, though it lacks the scale and international footprint of major competitors.
Industry Context
PharmaSGP Holding SE operates in Pharmaceuticals & Life Sciences.
Key facts
Founded: 2009 · Headquarters: Grafelfing, Germany · Employees: 91 · Revenue: ~$131M (trailing twelve months as of August 2025) · Market cap: €326M (as of May 2026)